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Entry of human immunodeficiency virus type 1 (HIV-1) into target cells is 
mediated by its envelope protein gp41 through class I membrane fusion.  
Interaction of two extra-virion heptad repeats (HRs) in the gp41 plays a pivotal 
role in the fusion and its inhibitor, enfuvirtide (T-20) blocks HIV-1 entry.  To 
identify agents that block HIV-1 fusion, two screening methods based on detection 
and quantification by the enzyme-linked immunosorbent assay (ELISA) principle 
have been established.  One method uses an alkaline phosphatase 
(ALP)-conjugated antibody (Ab-ELISA) and the other uses an ALP-fused HR 
(F-ELISA) to detect and quantify the interaction of the two HRs.  The F-ELISA 
was more simple and rapid, since no ALP-conjugated antibody reaction was 
required.  Both ELISAs detected all the fusion inhibitors tested except for T-20.  
Interaction of the two HRs was observed in both ELISAs, even in the presence of 
10% dimethyl sulfoxide.  Ab-ELISA performed best in a pH ranging from 6 to 8 
while F-ELISA performed best in a pH ranging from 7 to 8.  These results 
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indicate that our established ELISAs are suitable for the identification of HIV-1 
fusion inhibitors.   




1.  INTRODUCTION 
Combination chemotherapy has been widely used and reduces the mortality 
caused by HIV-1 infection.  During prolonged therapy, however, in some patients, 
such efficacy is attenuated by the emergence of drug resistant variants (Calmy et al., 
2004).  Moreover, combination chemotherapy occasionally induces various adverse 
effects and may also increase the costs of the therapy.  Therefore, development of 
novel anti-HIV-1 drugs that suppress replication of resistant variants, and are less toxic 
and less costly is urgently needed.   
There are at least two approaches to controlling replication of resistant 
variants and/or to reducing unfavorable adverse effects induced by the therapy.  One 
approach is the development of anti-HIV-1 drugs which inhibit new targets such as 
viral integrase (Hazuda et al., 2004) or cellular receptors such as CCR5 (Tagat et al., 
2004).  Actually, an integrase inhibitor, raltegravir (Grinsztejn et al., 2007), and a 
CCR5 antagonist, maraviroc (Fatkenheuer et al., 2005) have been approved for clinical 
application.  The other is the development or modification of current drugs that 
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inhibit well-established targets, to make them effective against resistant variants while 
reducing adverse side-effects.  In this study, we focus on the recently established and 
promising target of virus-cell membrane fusion. 
The mechanism of virus-cell membrane fusion has already been disclosed 
(Eckert and Kim, 2001).  Briefly, one of the HIV-1 envelope glycoproteins, gp120, 
binds to the host cell receptor CD4 and CXCR4 or CCR5, and then, another 
membrane-spanning protein gp41 in trimer anchors itself to the host cell membrane.  
After anchoring, heptad repeats 1 and 2 (HR1 and HR2), which are two extra-virion 
α-helical regions in the gp41, form an anti-parallel 6-helical bundle and lead to fusion 
of HIV-1 with the host cell membrane.  On the basis of this molecular mechanism, 
compounds which prevent 6-helical bundle formation will be potential HIV-1 fusion 
inhibitors.  Enfuvirtide (T-20) is the first peptide approved and used against HIV-1 
variants that are refractory to the effect of reverse transcriptase and protease inhibitors 
(Lalezari et al., 2003; Lazzarin et al., 2003).  Previously, we and others have 
developed novel potent fusion inhibitors, in the form of gp41 HR2-derived peptides 
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(Bewley et al., 2002; Otaka et al., 2002; Root et al., 2001) (Fig. 1) and small molecules 
(Cai and Gochin, 2007; Frey et al., 2006).  However, no fusion inhibitors, except for 
T-20 have yet been approved for clinical use.  To screen further potential fusion 
inhibitors, we have established two simple, rapid and reproducible in vitro screening 
systems using the enzyme-linked immunosorbent assay (ELISA). 
 
2.  MATERIALS AND METHODS 
2.1.  Antiviral agents 
The peptide-based fusion inhibitors were synthesized as described previously 
(Otaka et al., 2002), and their sequences are shown in Fig. 1.  CCR5 antagonist 
TAK-779 (Baba et al., 1999) was provided by Takeda Pharmaceutical Company, Ltd 
(Osaka, Japan) through an AIDS research and reference reagent program.  CXCR4 
antagonist AMD-3100 (De Clercq et al., 1994) was provided by S. Shigeta (Fukushima 
Medical University, Fukushima, Japan).  Adsorption inhibitor dextran sulphate MW 
5000, DS-5000 (Baba et al., 1988) was purchased from Sigma (St. Louis, MO, USA).   
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2.2.  Protein expression and purification 
A DNA fragment of the alkaline phosphatase (ALP) coding region without its 
secretory signal sequence, corresponding to amino acids 22-471 (Dodt et al., 1986; 
Kikuchi et al., 1981), was amplified by PCR from the E. Coli JM109 genome (K12 
strain; GenBank accession number: U00096).  The amplified ALP region was ligated 
into the pET32a vector (Novagen, Madison, WI, USA) to create pET32-ALP, a 
thioredoxin (TRX)-ALP fusion construct.  A DNA fragment coding the HR1 region of 
HIV-1 gp41, amino acid positions 18-73, was amplified by PCR from an HIV-1 
molecular clone pNL4-3 (GenBank accession number: AF324493).  The amplified 
HR1 region was ligated into the pMAL-C2 vector (New England Biolabs, Ipswich, 
MA, USA) to express HR1 with maltose binding protein (MBP) as a tag, designated 
pMAL-HR1.  The HR2 region, gp41 amino acid positions 112-150, was also 
amplified and ligated into both the pGEX-5X vector (GE Healthcare, Buckinghamshire, 
UK) and the pET32-ALP construct to express HR2 fusion protein with glutathione 
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S-transferase (GST) and TRX-ALP, designated pGEX-HR2 and pET32-ALP-HR2, 
respectively.  All vectors were verified by DNA sequencing and transformed into E. 
Coli BL21-CodonPlus (DE3)-RIL strain (Stratagene, La Jolla, CA, USA) for bacterial 
expression.  The expressed MBP-HR1, GST-HR2 and TRX-ALP-HR2 proteins were 
purified by Amylose Resin (New England Biolabs), Glutathione Sepharose 4B (GE 
Healthcare) and Ni-NTA Agarose (QIAGEN, Valencia, CA, USA), respectively, 
according to the manufacturers’ recommended protocols.  Purity was determined by 
SDS-PAGE and concentration by the Bradford protein assay (Bio-Rad, Hercules, CA, 
USA).  
 
2.3.  Indirect detection of interaction of HR1 and HR2 (Ab-ELISA) (Fig. 2A) 
 Fifty nanomolar MBP-HR1 dissolved in 50 mM sodium carbonate buffer (pH 
9.4) was coated on a 96-well ELISA plate (Costar, Cambridge, MA, USA) by 
incubation at 4ºC for 8 h.  After washing three times with PBS containing 0.025% 
Tween 20 (T-PBS) (pH 7.4), the plate was blocked using bovine serum albumin (BSA) 
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at a concentration of 1 mg/mL in T-PBS at 4ºC for 2.5 h, and then washed again as 
described above.  The MBP-HR1 on the plate was allowed to bind GST-HR2 (50 nM) 
by incubation at 37ºC for 1.5 h in the presence or absence of various concentrations of 
compounds for testing.  After washing, binding of GST-HR2 was detected by using 
alkaline phosphatase (ALP)-conjugated anti-GST antibody (Sigma) in 1: 2000 dilution 
at 4ºC for 1 h, then washed as before, prior to the addition of phosphatase substrate 
5-bromo-4-chloro-3-indolyl phosphate (BCIP) (BluePhos Microwell Phosphatase 
Substrate; KPL, Gaithersburg, MD, USA).  After incubating at room temperature for 
30 min, absorbance at 595 nm was measured by a plate reader (model 3550, Bio-Rad). 
 
2.4.  Direct detection of interaction of HR1 and HR2 (F-ELISA) (Fig. 2D) 
 All procedures were performed as described above, except that 
TRX-ALP-HR2 (50 nM) was used in place of GST-HR2, with binding directly 
detected by BluePhos Microwell Phosphatase Substrate without the interaction of 
ALP-conjugated anti-GST antibody. 
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2.5.  Anti-HIV activity 
Anti-HIV-1 activity was determined by the multinuclear activation of a 
galactosidase indicator (MAGI) assay as described previously (Kimpton and Emerman, 
1992; Kodama et al., 2001).  Briefly, the MAGI cells (104 cells/well) were seeded in 
flat bottom 96-well microtitre plates.  The following day, the cells were inoculated 
with HIV-1 and cultured in the presence of various concentrations of inhibitors in fresh 
medium.  After 48 h incubation, all the blue cells stained with 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) in each well were counted. 
 
3.  RESULTS 
3.1.  Establishment of ELISA 
To establish a novel assay system representing the specific interaction of HR1 
and HR2 regions of the HIV-1 gp41 protein, a simple ELISA was first established with 
ALP-conjugated antibody (Ab-ELISA) as shown in Fig. 2A.  MBP-HR1 was coated 
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onto a 96-well ELISA plate.  After blocking with BSA, GST-HR2 solution was added 
to the MBP-HR1 coated well.  Using ALP-conjugated anti-GST antibody, the 
interaction of HR1 and HR2 was colorimetrically measured by a plate reader.  Agents 
that block the interaction of HR2 with HR1 can reduce optical density at 595 nm 
(OD595).  The period for efficient coating of MBP-HR1 to the plate was measured by 
detection of ALP-conjugated anti-MBP antibody.  After 8 h and up to 24 h little 
increase in efficiency of MBP-HR1 coating was observed (data not shown).  When 
coating and blocking were performed prior to the assay, total time of procedure, 
excluding washing, was only 3 h. 
Prior to evaluation of fusion inhibitors, we examined interaction of GST-HR2 
with the MBP-HR1 coating.  We first coated MBPs with or without HR1 at a 
concentration of 50 nM, incubated them with various concentrations of GST-HR2, and 
then detected bound GST-HR2 with anti-GST antibody.  GST-HR2 interacted with 
MBP-HR1 in a dose-dependent manner, at least up to 100 µM and provided sufficient 
OD595 values, over 1.0 (Fig. 3).  Thus, 50 nM of GST-HR2 was used for further 
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experiments.   
Next, we modified the Ab-ELISA by using ALP-fused HR2 instead of 
GST-HR2 in the reaction with coated MBP-HR1, as shown in Fig. 2D (F-ELISA).  
The ALP-fused HR2 enables us to directly detect the HR1 and HR2 interaction without 
the antibody reaction step, thus providing an even more rapid and simple procedure 
than the Ab-ELISA which uses ALP-conjugated antibody for detection.  The total 
time required for the F-ELISA, excluding coating and blocking, was approximately 2 h.  
These results demonstrate that the ELISA systems detect the interaction of HR1 and 
HR2 interaction, enables the screening of potential fusion inhibitors without the need 
for infectious HIV-1 material, and is both simple and rapid.   
 
3.2.  Inhibitory effect of HR2-derived peptides and other entry inhibitors 
The efficacy of the fusion inhibitory peptides C34, SC34EK and SC35EK and 
other compounds was determined by both Ab-ELISA (Fig. 2A) and F-ELISA (Fig. 2D).  
Both ELISAs only detected the activities of these three fusion inhibitory peptides, but 
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not of other entry inhibitors (Table 1).  The inhibitory effects of these peptide fusion 
inhibitors were reproducible and displayed a sigmoidal dose-dependent curve (Fig. 2B, 
2E).  These results suggested that our established ELISAs were specific to the 
interaction between HR1 and HR2 in the fusion process.  Higher sensitivities for 
peptides tested were obtained by F-ELISA compared with those by Ab-ELISA (Table 
1).  However, compared with the MAGI assay, sensitivities of both ELISAs were 
between 14-50 fold lower.  Neither ELISA technique was able to detect the inhibitory 
effect of T-20, which has anti-fusion activity in vitro and in vivo, even though the gp41 
amino acid region 23 to 58, which is a predictive site for T-20 interaction, is included 
in the MBP-HR1 fusion protein (Fig. 1, Fig. 2C, 2F, Table 1).  We further examined 
the effect on T-20 susceptibility of changing the coating and interaction.  In this 
experiment, first GST-HR2 was coated, then exposed to MBP-HR1, and finally 
detected by anti-MBP antibody.  Again C34 and its derivatives worked, but T-20 did 
not (data not shown).   
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3.3.  Effect of DMSO concentration and pH 
 For screening, compounds are frequently dissolved in dimethyl sulfoxide 
(DMSO).  However, high concentrations of DMSO (over 1%) reduce cell viability in 
the cell-based assay, e.g., MAGI assay.  Our ELISA systems do not require cells, thus 
should be less influenced by DMSO concentration compared to the MAGI assay.  To 
verify this, we determined the concentration of DMSO that affects the interaction of 
HR1 and HR2 in our ELISAs.  In both the Ab- and F-ELISAs, DMSO concentrations 
up to 10% did not influence the optical densities to any great extent (Fig. 4A).  At 
these concentrations, optical densities recorded were less than 20% lower compared to 
those recorded in the absence of DMSO, indicating that the sensitivities of these tests 
would be sufficient to screen compounds that are dissolved in reagents containing up 
to 10% DMSO. 
Next, we investigated the effect of pH on detection by ELISA.  High 
concentrations of some compounds that are highly acidic or basic may decrease 
viability of the cells in cell-based assays.  The pH of the reaction buffer was modified 
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by addition of HCl and NaOH as control acidic or basic compounds, respectively.  In 
the F-ELISA, binding of HR1 and HR2 was 2-2.5 fold greater at pH less than 7 than at 
pH 7.4, while in the Ab-ELISA, the binding was relatively stable at pH 6 (Fig. 4B) and 
reduction of HR1 and HR2 binding was less than 20%.  On the other hand, in basic 
pH, binding of HR1 and HR2 were relatively stable up to pH 9 in both ELISAs.  
These results indicate that both systems are less influenced by DMSO concentrations 
up to 10% and in basic reaction conditions compared to cell-based assays.  However, 
in acidic reaction conditions, interaction of HR1 and HR2 is likely to be overestimated 
in the F-ELISA. 
 
4.  DISCUSSION 
 Our newly established ELISA systems successfully detected the HIV-fusion 
inhibitory activities of C34 a peptide based fusion inhibitor (Fig. 1) and its derivatives 
in a dose-dependent manner.  However, T-20 lacking the N-terminal 10 amino acids 
of C34 but containing an additional 12 amino acids in the C-terminal region showed 
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activity in neither of the ELISA systems (Fig. 2, Table 1).  T-20 is believed to inhibit 
6-helical bundle formation through competition with the physiological HR2 region of 
gp41.  This hypothesis is strongly supported by the introduction of a site of mutations 
for T-20 resistance in vivo.  Variants isolated from T-20 treated patients frequently 
display mutations in the HR1 region, especially at amino acids 36 to 45, including 
D36G/V/S, V38A/E and N43D (Aquaro et al., 2006; Cabrera et al., 2006; Mink et al., 
2005; Poveda et al., 2002; Rimsky et al., 1998; Wei et al., 2002) (Fig. 1).  
Interestingly, amino acid positions 36 to 45 are also crucial for C34 binding, and some 
C34 resistant variants also show cross resistance to T-20 (Nameki et al., 2005).  
Moreover, our preliminary data in the time course of addition experiments showed that 
the profile of inhibition is identical between C34 and T-20 (data not shown).   
Our designed MBP-HR1 contains the presumed interaction site of T-20 (amino 
acid positions 23-58), as determined by crystal structure analysis of the N36-C34 
complex (Chan et al., 1997) (Fig. 1).  However, we failed to detect T-20 inhibitory 
activity in our ELISA systems (Fig. 2C, 2F).  To the best of our knowledge, there are 
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no reports that describe the potent activity of T-20 in protein- or peptide-based assays 
(Cai and Gochin, 2007; Huang et al., 2006; Huang et al., 2007; Jiang et al., 1999; Liu 
et al., 2007; Ryu et al., 1998; Xu et al., 2007).   
In this regard, two groups have tried to reveal the mechanism of action of T-20 
mainly through physicochemical experiments, with both groups proposing that T-20 
may act through the lipid membrane.  Jiang et al. has proposed that HR2 peptides 
have two different functional domains, an HR1 binding domain, and a lipid binding 
domain (Liu et al., 2007).  C34 contains an HR1 binding sequence but not a lipid 
binding domain, while T-20 has only a lipid binding domain, suggesting that T-20 
might be functional only in the presence of lipid membrane.  Shai et al. also found 
that the C-terminal region of T-20 which was not included in C34 could be replaced 
with fatty acid, indicating that T-20 acts through the lipid membrane (Wexler-Cohen 
and Shai, 2007).   
It is possible that MBP hampers the proper conformation of HR1.  However, 
in the 6-helix bundle crystal structure of human T cell leukemia virus type 1 gp21, 
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MBP remained fused to the N-terminal of HR1 (Kobe et al., 1999).  Thus, it is 
unlikely that the inability of HR1 to bind T-20 is due to improper conformation of HR1.  
Moreover, even synthetic peptides of HR1 and T-20 do not bind each other (Liu et al., 
2005).   
To date, several peptide based detection systems have been reported, although 
they failed to demonstrate T-20 activity.  Most of them utilize the NC-1 monoclonal 
antibody which recognizes discontinuous epitopes presented on the 6-helix complex 
between N36 and C34 to detect 6-helical conformations (Huang et al., 2006; Huang et 
al., 2007; Jiang et al., 1999; Liu et al., 2007).  It is predicted that this system may not 
detect the peptide-based fusion inhibitor C34 itself or may not detect C34 derivatives, 
since the antibody NC-1 was derived from the 6-helix conformation of N36 and C34 
peptides.  Ryu et al. also reported similar ELISA systems (Ryu et al., 1998), but 
showed an inhibitory effect only for C51 with an EC50 value of 1.0 µg/ml 
(approximately 200 nM).  Other groups have reported the development of assay 
systems using fluorescence resonance energy transfer (FRET) (Cai and Gochin, 2007; 
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Xu et al., 2007).  Although FRET requires no coating and washing steps, it seems to 
be less sensitive compared to our ELISA systems.  In fact, EC50 values of C34 in the 
FRET system were described as approximately 5 µM (Xu et al., 2007), while those in 
our Ab-ELISA and F-ELISA were 365 and 59 nM, respectively (Table 1).   
 The sensitivities of our ELISA systems were lower than those of the 
cell-based MAGI assay (Table 1).  However, the ELISA systems could detect the 
interaction between HR1 and HR2 even at a high concentration of DMSO, and in a 
relatively wide pH range (Fig. 4), indicating their capacity for screening of highly 
concentrated compounds.  Decreased concentrations of MBP-HR1 and GST-HR2 or 
ALP-HR2 increase the anti-viral sensitivity, although this also reduces detection 
sensitivity of ALP activity.  Detection sensitivity could be increased by using a highly 
sensitive chemiluminescent probe as an alternative to the BCIP substrate we used, but 
at the first screening, cytotoxic effect of compounds will be low, so higher 
concentrations of compounds can be used.   
At pH greater than 8, both ELISAs showed decreased optical density, while at 
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pH less than 7, enhanced ALP activity was observed in F-ELISA compared with the 
neutral pH 7.4 (Fig. 4B).  Although we could not elucidate the detailed mechanism at 
present, even in Ab-ELISA, the optical density was also enhanced by using an acidic 
buffer in the incubation of GST-HR2 with anti-GST antibody (data not shown).  Thus, 
low pH enhances ALP activity rather than enhancing the interaction of HR1 and HR2.  
These results indicate that we should take note of this artificial enhancement when 
acidic compounds are screened by F-ELISA. 
 At the virus-cell membrane fusion step, the interaction between viral envelope 
proteins HR1 and HR2 is a common mechanism of class I fusion (Jahn et al., 2003; 
Schibli and Weissenhorn, 2004).  It is expected that establishment of a similar ELISA 
screening system for other viruses using class I fusion for cell entry, such as influenza 
virus (Eckert and Kim, 2001), feline immunodeficiency virus (FIV) (Medinas et al., 
2002), severe acute respiratory syndrome coronavirus (SARS-CoV) (Bosch et al., 
2004) and Ebola virus (Watanabe et al., 2000) is possible.  For some highly virulent 
agents, such as SARS-CoV and Ebola virus, our system will be an extremely useful 
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tool since it does not require infectious material.   
 In this study, we have developed two novel in vitro assay systems for fusion 
inhibitors by focusing on the interaction of envelope proteins HR1 and HR2.  
Hydrophobic pocket in HR1 and tryptophan rich domain in HR2 acting as “pocket” 
and “knob”, respectively, play a key role in the virus-cell membrane fusion process, 
indicating that these interactions are an attractive target for small molecule fusion 
inhibitors (Ferrer et al., 1999).  Interestingly, C34, GST-HR2 and ALP-TRX-HR2 
used in this study contain “knob” region but T-20 does not.  The developed systems 
are also ideal for initial screenings because of low variability and good reproducibility 
even at high compound concentration, and since they allow for a non-infectious rapid 
and simple procedure.  These assays will be useful for the discovery of novel fusion 
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Fig. 1.  Schematic view of gp41.  The locations of the fusion peptide (FP), 
N-terminal heptad repeat region (HR1), C-terminal heptad repeat region (HR2), 
transmembrane domain (TM) and amino acid sequence of HR1, HR2, T-20, C34 and 
its derivatives (Otaka et al., 2002) are shown.  The residue numbers of each peptide 
correspond to their positions in the envelope protein gp41 of HIV-1 NL4-3 clone.  
Representative regions of HR1 and HR2 used in this study are defined by the amino 
acids 18-73 and 112-150, respectively, and designated as MBP-HR1 and GST-HR2 or 
TRX-ALP-HR2 fused protein as described in materials and methods section.  The X 
in SC34EK indicates an artificial amino acid norleucine instead of methionine, to 
avoid oxidation of the methionine residue. 
 
 
Fig. 2.  Flow chart of our established ELISA systems (A and D) and the inhibitory 
effects of peptide-based fusion inhibitors determined by these systems (B, C, E and F).  
The schematics of Ab-ELISA and F-ELISA are shown.  In Ab-ELISA (A), GST-HR2 
interacts with MBP-HR1 on the ELISA plate, and the amounts of GST-HR2 are 
quantified by using ALP-conjugated anti-GST antibody and ALP substrate.  In the 
presence of fusion inhibitors, GST-HR2 can not interact with MBP-HR1, resulting in 
no ALP activity.  In F-ELISA (D), ALP-fused HR2 protein enables the detection of 
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the interaction of HR2 directly without ALP-conjugated anti-GST antibody.  
Inhibition curves of binding by Ab-ELISA (B) and F-ELISA (E) at peptide 
concentrations 10-10 to 10-5 M are illustrated.  The actual appearance of ELISA plates 
observed in Ab-ELISA (C) and F-ELISA (F) is shown. 
 
Fig. 3.  The binding efficacy of GST-HR2.  Fifty nM of MBP-HR1 (circle), MBP 
(square) and mock (triangle with broken line) were coated on the plate.  Various 
concentrations of GST-HR2 were added and incubated at 37ºC for 1.5 h.  Bound 
GST-HR2 was detected with ALP-conjugated anti-GST antibody by measuring the 
optical density at 595 nm (OD595). 
 
Fig. 4.  Effects of DMSO concentration and pH.  The effect of DMSO from 0.1 to 
50% added to the reaction of HR1 and HR2 is shown (A).  Binding is expressed as a 
percentage of that in the absence of DMSO.  Alteration of the pH from 2 to 12 at the 
HR1 and HR2 reaction was performed by using HCl or NaOH (B).  Binding is 
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Table 1.  The efficacy of HR2-derived peptides and other entry inhibitors as 
determined by Ab- or F-ELISAs and the cell-based MAGI assay.   
   EC50 (nM)a 
   MAGId 
 
 C34g  365±43  59±7.7  4.0±0.86 N.D.h 
 SC34EKg 41±5.0 21±3.2 1.6±0.61 N.D. 
 SC35EKg 38±3.0 16±2.8 0.35±0.030 N.D. 
 T-20g >10,000 >10,000       35±17 N.D. 
 TAK-779 >100,000 >100,000 >100,000 1.85±0.19 
 AMD-3100 >100,000 >100,000 0.39±0.030 >100,000 
 DS-5000 >100,000 >100,000 19±6.0 348±46 
a EC50 refers to the concentration of peptides which show 50% inhibition relative to the 
control.   
b The amount of binding GST-HR2 measured by ALP-conjugated anti-GST antibody.   
c Direct detection of HR1 and HR2 interaction without antibody reaction by using 
ALP-fused HR2 protein.   
d Multinuclear activation of a galactosidase indicator assay using HeLa 
CD4-LTR/β-galactosidase indicator cells (Kimpton and Emerman, 1992).   
e CXCR4 (X4) tropic HIV-1 strain.   
f CCR5 (R5) tropic HIV-1 strain.   
g All peptide sequences are shown in Fig. 1.   
h N.D. = not determined.   
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